Oncology drug development faces unmatched pressures as biopharmaceutical companies race for treatments to help millions of patients globally. With roughly 5% of patients participating in clinical research, oncology studies struggle to recruit patients, find qualified investigators and keep patients enrolled in studies. PPD and Optimal Research are solving these challenges through a data-driven approach exploring multiple channels of patient access paired with 2 weeks site activation.

Through advanced data mining, electronic medical record overlays, site imbedded staff and a pre-qualified oncology research community, we identify the right patients—where they live—unlocking the potential of sites and transforming oncology drug development.

In this webinar, we will explore ideas on how we are changing the face of oncology drug development, including:

  • Challenging long-time clinical and operational approaches to oncology clinical trials to conduct studies in community practice environments.
  • Recruiting patients directly from their communities, enhancing diversity and engaging treatment-naive patient groups.
  • Matching sites and trials more effectively through innovative data analysis to identify the right investigators and the right patients.
  • Treating patients in their local environment to provide unmatched engagement benefits, ease participation and leverage their support networks.


Rhonda Henry,
Vice President, Site Networks and Patient Centricity

As vice president of site networks and patient centricity, Rhonda Henry develops PPD’s site network strategies and patient-centric trial models to improve our sites and patients’ capabilities and expand our service offerings. Rhonda works closely with external organizations and PPD’s partner site networks to continuously expand PPD’s site and patient access capabilities.

Rhonda most recently serviced as vice president of alliance management, leading PPD’s efforts to cultivate new alliance relationships while continuing to grow the company’s existing alliances. She held roles of increasing leadership within the alliance management team, increasing margins, expanding the breadth of services to alliance clients, broadening market share and enhancing client satisfaction.

Krystyna Kowalczyk,
Chief Operating Officer, Optimal Research

Krystyna Kowalczyk, leads our oncology enrollment enhancement initiative within the Optimal Research business unit. Krystyna has over 25 years of experience in clinical research operations with the majority specifically within oncology trial operations.

Krystyna was a founding partner in a small oncology CRO in 1997 looking to drive clinical trial innovation. As the first eCRO eventually selling to a larger global organization she was able to successfully challenge current paradigms and build an innovative organization with an oncology focus. As her next step into challenging paradigms and driving innovation, Krystyna joined Optimal Research to tackle the challenge of oncology patient enrollment.

Shannon Macquarrie,
Executive Director, Global Project Management

Shannon Macquarrie is executive director of hematology/oncology in global project management at PPD. In this role, she oversees oncology programs and work to establish collaborative strategies in support of operational delivery. Shannon has deep experience managing a global cross-functional team, providing direction and oversight to support biotech and biopharma partners along with departmental and corporate goals. She is accountable for project, program and pipeline delivery, including resourcing programs.

Shannon rejoined PPD in 2016 following 7 years at another large CRO in a similar role, where she first led a global team of project leaders and directors in the peri/post approval division, followed by oversight of a global department of PI-IV cross-therapeutic project managers dedicated to large strategic partnerships. Prior to this, she held roles of increasing responsibility across clinical and project management functions at other clinical and academic research organizations.


Title: More Patients, Faster. The Next Evolution of Oncology Drug Development

Date: Tuesday, July 24, 2018

Time: 10:00 AM Eastern Daylight Time

Duration: 1 hour

Register Now:

This site is owned and operated by Informa plc ("informa") whose registered office is 5 Howick place, London SW1P 1WG. Registered in England and Wales Number 1072954.
Privacy Policy | Terms